The Clinical Trials Office Core (CTO) provides comprehensive clinical trials resources and support to KCI members and affiliate institutions with the highest priority being the safety of participating subjects. The CTO functions to the highest ethical standards ensuring and maintaining compliance of KCI ciinicai trials with internal policies and external governing bodies. The primary and continuing goals ofthe CTO are to: Ensure that all clinical trials conducted at KCI are carried out in strict compliance with the Code of Federal Regulations (CFR) and in accordance with Intemationai Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. This is done in conjunction and with oversight by the Wayne State University Human Investigation Committee. Facilitate and optimize accrual to clinical trials by providing well qualified, specifically trained data management and research nurse support to KCI physicians and clinical support staff. Ensure research coordination by facilitating and optimizing physician-patient-CTO staff interaction, communication and collaboration. Facilitate regulatory approval and oversight to rapidly review and activate appropriate trials. The CTO coordinates and ensures compliance with the Data and Safety Monitoring Plan (DSMP), which irilSlu'des coordination and administrative support to the Protocol Review and Monitoring Committee, the Data and Safety Monitoring Committee and the Quality Assurance Committee. Additionally, the CTO serves as an interface with the protocol specific IRB of record to facilitate preparation of required regulatory documents necessary to expedite timely approval of KCI protocols. The CTO also coordinates registration and maintenance of all therapeutic protocols to the NCI's Clinical Trial Reporting Program and ClinicalTrials.gov. CTO supports NCI-funded peer reviewed protocols, investigator-initiated studies, industry sponsored protocols and the cooperative group protocols of SWOG, COG, GOG, RTOG, as well as other specialty cooperative groups. Over 80 FTEs provide data management services as members of the CTO in support of approximately 350 active protocols. These activities have resulted in a 76% increase in accrual to therapeutic clinical trials during this grant period with representation of minorities and women that reflect the communitv that KCI serves.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA022453-33
Application #
8780616
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-12-01
Budget End
2015-11-30
Support Year
33
Fiscal Year
2015
Total Cost
$261,216
Indirect Cost
$89,363
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Kraniak, Janice M; Chalasani, Anita; Wallace, Margaret R et al. (2018) Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening. Exp Neurol 299:289-298
An, Myunggi; Yu, Chunsong; Xi, Jingchao et al. (2018) Induction of necrotic cell death and activation of STING in the tumor microenvironment via cationic silica nanoparticles leading to enhanced antitumor immunity. Nanoscale 10:9311-9319
Neslund-Dudas, Christine M; McBride, Russell B; Kandegedara, Ashoka et al. (2018) Association between cadmium and androgen receptor protein expression differs in prostate tumors of African American and European American men. J Trace Elem Med Biol 48:233-238
Wu, Jheng-Yu; Xiang, Shengyan; Zhang, Mu et al. (2018) Histone deacetylase 6 (HDAC6) deacetylates extracellular signal-regulated kinase 1 (ERK1) and thereby stimulates ERK1 activity. J Biol Chem 293:1976-1993
Negmeldin, Ahmed T; Knoff, Joseph R; Pflum, Mary Kay H (2018) The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. Eur J Med Chem 143:1790-1806
Tamura, Koji; Yu, Jun; Hata, Tatsuo et al. (2018) Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Proc Natl Acad Sci U S A 115:4767-4772
Matherly, Larry H; Hou, Zhanjun; Gangjee, Aleem (2018) The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer. Cancer Chemother Pharmacol 81:1-15
Pollack, Murray M; Holubkov, Richard; Reeder, Ron et al. (2018) PICU Length of Stay: Factors Associated With Bed Utilization and Development of a Benchmarking Model. Pediatr Crit Care Med 19:196-203
Bao, Xun; Wu, Jianmei; Sanai, Nader et al. (2018) A liquid chromatography with tandem mass spectrometry method for quantitating total and unbound ceritinib in patient plasma and brain tumor. J Pharm Anal 8:20-26
Heath, Elisabeth I; Lynce, Filipa; Xiu, Joanne et al. (2018) Racial Disparities in the Molecular Landscape of Cancer. Anticancer Res 38:2235-2240

Showing the most recent 10 out of 826 publications